DEUCRAVACITINIB for Guttate psoriasis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where DEUCRAVACITINIB was used for Guttate psoriasis.
Most Reported Side Effects for DEUCRAVACITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 228 | 9.6% | 0 | 1 |
| Acne | 225 | 9.4% | 0 | 1 |
| Pruritus | 187 | 7.8% | 0 | 2 |
| Rash | 175 | 7.3% | 0 | 0 |
| Erythema | 124 | 5.2% | 0 | 2 |
| Psoriasis | 122 | 5.1% | 0 | 2 |
| Off label use | 101 | 4.2% | 1 | 6 |
| Adverse event | 74 | 3.1% | 0 | 0 |
| Mouth ulceration | 72 | 3.0% | 0 | 1 |
| Folliculitis | 65 | 2.7% | 0 | 2 |
| Headache | 65 | 2.7% | 0 | 0 |
| Product dose omission issue | 61 | 2.6% | 0 | 0 |
| Pain | 60 | 2.5% | 0 | 1 |
| Skin burning sensation | 60 | 2.5% | 0 | 1 |
| Diarrhoea | 46 | 1.9% | 1 | 3 |
Other Indications for DEUCRAVACITINIB
Psoriasis (1,456)
Product used for unknown indication (808)
Psoriatic arthropathy (41)
Eczema (10)
Pustular psoriasis (10)
Dermatitis atopic (8)
Palmoplantar pustulosis (6)
Dermatitis (5)
Erythrodermic psoriasis (5)
Granuloma annulare (5)
Other Drugs Used for Guttate psoriasis
APREMILAST (285)
ADALIMUMAB (136)
SECUKINUMAB (86)
RISANKIZUMAB-RZAA (64)
IXEKIZUMAB (57)
ETANERCEPT (56)
USTEKINUMAB (33)
GUSELKUMAB (32)
CLOBETASOL (19)
CERTOLIZUMAB PEGOL (17)